Home › Research › Biomarkers
In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model
Setti SE, Raymick J, Hanig J, Sarkar S.. Journal of neuroscience methods, 2021-01-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Congo Red (CR) has been used for its binding affinity to amyloid fibrils for the better part of a century. Recently, our laboratory has demonstrated its ability to bind to tau protein as well. New method Here we describe a novel methodology for fast, thorough, whole-brain labeling of amyloid plaques with CR via perfusion. We tested five different variants which altered the volume of CR, the speed of perfusion, and the solution CR was solubilized in to determine the best results. Results and conclusion We determined that intra-cardiac perfusion of animals with 0.5 % CR in 100 ml of 50 % ethanol or perfusion with 0.5 of CR in 100 ml of 10 % neutral buffer formalin both perfused at a rate of 30 ml/min for 3.3 min resulted in the clearest CR labeling, with little to no background noise. Both variants were compatible with subsequent immunolabeling procedures for NU-1, as well as Ferritin and GFAP. Compared to traditional CR plaque labeling methodology, this new method allows for quick whole brain CR-labeling. This reduces the amount of time from days to mere minutes. It also reduces potential for variability that would result from staining slides in batches. Thus, CR-perfusion is a rapid, thorough method that can be utilized to rapidly stain amyloid in the rodent brain.
What this study adds
Evidence grade: Low
This is a laboratory method in rats for staining amyloid plaques with Congo Red via perfusion, not a treatment or prevention study. Reported effect size: or 3.3.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Setti, S. E., Raymick, J., Hanig, J., & Sarkar, S. (2021). In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model. Journal of neuroscience methods. https://doi.org/10.1016/j.jneumeth.2021.109082
Vancouver
Setti SE, Raymick J, Hanig J, Sarkar S. In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model. Journal of neuroscience methods. 2021. doi:10.1016/j.jneumeth.2021.109082. PMID: 33508413.
BibTeX
@article{setti2021-33508413,
author = {Setti, S. E. and Raymick, J. and Hanig, J. and Sarkar, S.},
title = {{In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model}},
journal = {Journal of neuroscience methods},
year = {2021},
doi = {10.1016/j.jneumeth.2021.109082},
pmid = {33508413},
url = {https://doi.org/10.1016/j.jneumeth.2021.109082}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Recently, our laboratory has demonstrated its ability to bind to tau protein as well.
- We tested five different variants which altered the volume of CR, the speed of perfusion, and the solution CR was solubilized in to determine the best results.
- Results and conclusion We determined that intra-cardiac perfusion of animals with 0.5 % CR in 100 ml of 50 % ethanol or perfusion with 0.5 of CR in 100 ml of 10 % neutral buffer formalin both perfused at a rate of 30 ml/min for 3.3 min resulted in the clearest CR labeling, with little to no background noise.
- Compared to traditional CR plaque labeling methodology, this new method allows for quick whole brain CR-labeling.
- It also reduces potential for variability that would result from staining slides in batches.
Why it matters
This is a laboratory method in rats for staining amyloid plaques with Congo Red via perfusion, not a treatment or prevention study. It may speed up research staining from days to minutes, but it does not show any effect on treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect sizeor 3.3
- Evidence strengthLow
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neuroscience methods) |
| Journal's citation record | 2 / 4 | Journal of Neuroscience Methods: journal h-index 227 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “rat”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 16 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 2 / 6 | Cited 1.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Sumit Sarkar: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | United States Food and Drug Administration: institution h-index 651 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33508413) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.